Invesco
RCUS icon

Invesco’s Arcus Biosciences RCUS Stock Holding History

Invesco’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.7M Buy
820,820
+406,455
+98% +$8.78M ﹤0.01% 1513
2025
Q4 		$9.87M Buy
414,365
+121,961
+42% +$2.49M ﹤0.01% 1849
2025
Q3 		$3.98M Buy
292,404
+40,553
+16% +$422K ﹤0.01% 2337
2025
Q2 		$2.05M Sell
251,851
-2,173
-0.9% -$18.6K ﹤0.01% 2572
2025
Q1 		$1.99M Buy
254,024
+50,037
+25% +$580K ﹤0.01% 2553
2024
Q4 		$3.04M Buy
203,987
+35,905
+21% +$586K ﹤0.01% 2461
2024
Q3 		$2.57M Sell
168,082
-14,358
-8% -$226K ﹤0.01% 2509
2024
Q2 		$2.78M Sell
182,440
-8,243
-4% -$133K ﹤0.01% 2459
2024
Q1 		$3.6M Sell
190,683
-1,947
-1% -$33.7K ﹤0.01% 2415
2023
Q4 		$3.68M Sell
192,630
-40,174
-17% -$642K ﹤0.01% 2392
2023
Q3 		$4.18M Sell
232,804
-16,361
-7% -$329K ﹤0.01% 2298
2023
Q2 		$5.06M Sell
249,165
-33,954
-12% -$647K ﹤0.01% 2233
2023
Q1 		$5.16M Buy
283,119
+10,841
+4% +$207K ﹤0.01% 2200
2022
Q4 		$5.63M Buy
272,278
+5,764
+2% +$159K ﹤0.01% 2184
2022
Q3 		$6.97M Sell
266,514
-74,250
-22% -$1.96M ﹤0.01% 2021
2022
Q2 		$8.63M Buy
340,764
+47,290
+16% +$1.16M ﹤0.01% 1950
2022
Q1 		$9.26M Buy
293,474
+94,844
+48% +$3.18M ﹤0.01% 2000
2021
Q4 		$8.04M Sell
198,630
-26,054
-12% -$1.01M ﹤0.01% 2140
2021
Q3 		$7.83M Buy
224,684
+6,331
+3% +$197K ﹤0.01% 2142
2021
Q2 		$6M Sell
218,353
-79,524
-27% -$2.27M ﹤0.01% 2352
2021
Q1 		$8.36M Sell
297,877
-6,881
-2% -$239K ﹤0.01% 2066
2020
Q4 		$7.91M Buy
304,758
+18,492
+6% +$448K ﹤0.01% 1929
2020
Q3 		$4.91M Sell
286,266
-5,180
-2% -$116K ﹤0.01% 2017
2020
Q2 		$7.21M Buy
291,446
+5,155
+2% +$139K ﹤0.01% 1809
2020
Q1 		$3.97M Buy
+286,291
New +$3.56M ﹤0.01% 2012

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Invesco's RCUS Position: Q1 2026 in Review

Invesco increased its Arcus Biosciences (RCUS) stake by 98% in Q1 2026, buying an estimated $8.78M and bringing the position to 820,820 shares worth $17.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1513.

Invesco first reported a position in RCUS in Q1 2020 and has held it in 25 quarters since. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Invesco held 820,820 shares of Arcus Biosciences worth $17.7M as of Q1 2026.
  • Invesco bought 406,455 Arcus Biosciences shares in Q1 2026, an estimated $8.78M.
  • Arcus Biosciences made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #1513 holding.
  • Invesco first reported a position in Arcus Biosciences in Q1 2020 and has held it in 25 quarters since.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.